Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Scientific References TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial
Its essential to consult with your healthcare provider before stopping the medication
Marketed by: Novo Nordisk Inc., Plainsboro, NJ 08536 For information about OZEMPIC contact: Novo Nordisk Inc
FDA approves Novo Nordisks oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
Many researchers store cagrilintide alongside retatrutide or other peptides without any cross-contamination concerns
US$ 24.22
US$ 26.21
US$ 25.25
US$ 29.06
US$ 25.96
US$ 26.86
